Edgewise heart drug passes key trial test
Source ↗
👁 0
💬 0
Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.
Comments (0)